Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
This episode is essential listening for practitioners managing complex, multisystem female presentationsfrom hormone imbalances to unresolved histamine-related inflammation
The Phase 3 TRIUMPH-4 trial enrolled 445 adults with obesity and knee osteoarthritis for 68 weeks
injectable GLP-1 treatments: Which works better
As the BSO concentrations increased, total glutathione levels decreased as compared to the vehicle control
Long acting amylin receptor agonist, AZD6234, shows advantages over GLP-1 receptor agonist activation for leptin re-sensitization in a diet-induced obese (DIO) rat model
US$ 22.74
US$ 25.87
![In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
![Tirzepatide vs. Semaglutide: Which Weight Loss Drug Works Better? [May 2025 NEJM Study Explained]](https://belite.com/wp-content/uploads/2025/06/July-2025-Blog-Post-Belite.png)
US$ 25.73
